PALI - Palisade Bio Earnings growth forecast for next year

Palisade Bio, Inc. (PALI) is implementing AI and robotics to automate target discovery for gastrointestinal treatments. EPS growth prospects for the next fiscal year demonstrate how automated enzyme synthesis ensures drug purity, with the latest parameter standing at -32.10. The company is currently executing a strategic pivot of its R&D portfolio, optimizing expenses to preserve liquidity and focusing on targeted inflammation therapy.

palisadebio.com (PALI): Net earnings per share growth forecast for next year from 07/04/2022 to 11/13/2026

PALI (palisadebio.com): analytical breakdowns and indicator data

- price and consensus price forecast:

Price Chart Palisade Bio, Inc.|PALI - Forecast Levels Chart

- market capitalization statistics:

Market Capitalization Palisade Bio|PALI - Enterprise Value

- book capitalization indicators:

Net Assets per Single Share Palisade Bio|PALI - Company Book Value|Market Capitalization to Book Value Ratio palisadebio.com|PALI - Company Total Asset Base

- debt and liquidity details:

- net income and valuation ratios data:

PALI - Final Profit|Projected Future Earnings Palisade Bio, Inc.|PALI - Price to Earnings Ratio|Forward P/E Multiple Palisade Bio, Inc.|PALI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Palisade Bio|PALI - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Palisade Bio|PALI - Earnings per share for the trailing year|Quarterly EPS earnings growth palisadebio.com|PALI - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Palisade Bio, Inc.

Basic company analysis:Palisade Bio, Inc., PALI

Palisade Bio, Inc. (PALI) maintains a narrow specialization in the development of protease inhibitors, creating a binary risk where financial success depends directly on external partnerships. Analyzing the forward net income trend on GURU.Markets, an investor assesses market optimism regarding future earnings, while a sharp spike in the curve signals a conflict between expected returns and the risk of capital overvaluation.

Competing companies